Contributed Poster Presentations Session 2

INFECTIOUS DISEASES (PID) PID1 EFFICACY OF ZINC LOZENGES ON THE DURATION OF COMMON COLD SYMPTOMS: A META-ANALYSIS REVISITED Chaiyakunapruk N1, Veenstra DL1, Sullivan SD1, Saint S2, Bent S3, 1University of Washington, Seattle, WA, USA; 2University of Michigan, Ann Arbor, MI, USA; 3University of California, San Francisco, CA, USA PID2 IMPACT OF CYTOMEGALOVIRUS (CMV) -RELATED READMISSION ON POST HEART TRANSPLANT RESOURCE USE Leader S, Henderson R, Carlin D, MedImmune Inc, Gaithersburg, MD, USA PID3 TRENDS IN INPATIENT COSTS FOR ACUTE PANCREATITIS IN THE UNITED STATES Bell CF, Stephens JM, Botteman MF, Pashos CL, Ewing M, Abt Associates Clinical Trials, Bethesda, MD, USA PID4 ECONOMIC COST OF HIV INFECTION IN UNTREATED WORKERS: AN EMPLOYER'S PERSPECTIVE Chaikledkaew U1, Liu GG2, Lyu R3, Louie S1, 1University of Southern California, Los Angeles, CA, USA; 2University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; 3Rutgers University, New Brunswick, NJ, USA PID5 MOXIFLOXACIN VS AMOXICILLIN/CLAVULANATE IN THE TREATMENT OF ACUTE MAXILLARY SINUSITIS (AMS): EFFICACY, SAFETY AND PATIENT-REPORTED OUTCOMES IN PRIMARY CARE Rakkar S, Plano Medical Center, Plano, TX, USA PID6 HIV/AIDS HEALTH STATE UTILITIES USING COMMUNITY AND PATIENT PREFERENCE WEIGHTS: WHEN DOES IT MATTER? Schackman BR1, Goldie SJ1, Freedberg KA2, Losina E3, Brazier J4, Weinstein MC1, 1Harvard School of Public Health, Boston, MA, USA; 2Massachusetts General Hospital, Boston, MA, USA; 3Boston University School of Public Health, MA, USA; 4University of Sheffield, Sheffield, UK PID7 OBSERVATIONAL EVALUATION OF HEALTH STATE UTILITIES AMONG A COHORT OF SEPSIS PATIENTS Drabinski A, Williams G, Formica C, Knoll Pharmaceutical Company, Mount Olive, NJ, USA PID8 COSTS OF HEALTHCARE FOR HEPATITIS C-INFECTED MEMBERS IN A MANAGED CARE ORGANIZATION (MCO) Schaffer M1, Phillips AL2, Mansukani S1, 1Health Partners, Inc, Philadelphia, PA, USA; 2Thomas Jefferson University, Philadelphia, PA, USA PID9 COST-EFFECTIVENESS OF INTERFERON ALFA THERAPY FOR CHRONIC HEPATITIS C WITH CIRRHOSIS Hisashige A, Katayama T, Mikasa H, University of Tokushima, School of Medicine, Tokushima, Japan PID10 EFFECTS OF LINEZOLID ON HOSPITAL LENGTH OF STAY IN METHICILLIN-RESISTANT STAPHYLOCOCCUS INFECTIONS ESTIMATED FROM MULTIVARIATE SURVIVAL ANALYSIS Willke RJ1, Li ZJ2, Glick H3, Rittenhouse BE1, Hafkin B4, 1Pharmacia, Peapack, NJ, USA; 2Pharmacia Corporation, Kalamazoo, MI, USA; 3University of Pennsylvania, Philadelphia, PA, USA; 4Pharmacia Corporation, Portage, MI, USA PID11 PEGYLATED (40KDA) INTERFERON ALFA-2A (PEGASYS®) SIGNIFICANTLY IMPROVES TOLERABILITY, QUALITY OF LIFE, AND WORK PRODUCTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C Imperial J1, Thuluvath P2, Perrillo RP3, Rothstein KD4, Poulios NS5, Pappas SC5, Ackermann SP5, Doerschuk BS5, 1Stanford Medical School, Palo Alto, CA, USA; 2John Hopkins Hospital, Baltimore, MD, USA; 3Ochsner Clinic, New Orleans, LA, USA; 4Albert Einstein Medical Center, Philadelphia, PA, USA; 5Roche Laboratories Inc, Nutley, NJ, USA PID12 AVERTING FUTURE AIDS CASES: MODELING COSTS OF INTERVENTIONS WITH OUT-OF-TREATMENT SUBSTANCE ABUSERS Richter A, Loomis BR, Wechsberg WM, Research Triangle Institute, Research Triangle Park, NC, USA PID13 ECONOMIC EVALUATION OF ROTAVIRUS VACCINATION FOR THE NETHERLANDS Welte R, Jager J, van Duynhoven Y, de Wit M, National Institute of Public Health and the Environment, Bilthoven, Netherlands PID14 PREDICTORS OF THE MENTAL (MHS) AND PHYSICAL HEALTH SUMMARY (PHS) SCORES OF THE MOS-HIV IN A SAMPLE OF HIV-INFECTED PATIENTS Griffis DL, Delate T, Coons SJ, The University of Arizona, Tucson, AZ, USA PID15 MANAGING AIDS IN THE ERA OF ANTIRETROVIRAL THERAPY: CHANGES IN THE RATE AND COST OF HOSPITALIZATIONS O'Brien JA, Pierce D, Patrick AR, Caro JJ, Caro Research Institute, Concord, MA, USA PID16 COST BURDEN OF VARICELLA-ZOSTER VIRUS INFECTION IN A MANAGED CARE SETTING Schaffer M1, Liu M1, Scott W2, Mansukani S1, 1Health Partners, Inc, Philadelphia, PA, USA; 2Hospital of the University of Pennsylvania, Philadelphia, PA, USA PID17 ECONOMIC EVALUATION OF OSELTAMIVIR FOR INFLUENZA PATIENTS IN JAPAN Kobayashi M, Crecon Research and Consulting Inc, Tokyo, Japan PID18 METHICILLIN-RESISTANT STAPHYLOCOCCUS SPECIES TREATMENT PATTERNS IN CANADA Becker D, Rosner AJ, Innovus Research Inc, Burlington, ON, Canada PID19 AN ECONOMIC ANALYSIS OF CEFDINIR VERSUS LORACARBEF FOR TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS Shah SN12, Smith D1, Copley-Merriman C2, 1University of Michigan, Ann Arbor, MI, USA; 2Pfizer Pharmaceuticals Group, Ann Arbor, MI, USA PID20 TARGETING POPULATIONS AT-RISK FOR URINARY TRACT INFECTION COMPLICATION Doyle B, Hess G, CareScience, Philadelphia, PA, USA PID21 THE COST-EFFECTIVENESS ANALYSIS OF LAMIVUDINE IN THE TREATMENT OF CHRONIC HEPATITIS B IN POLAND Orlewska E, Unimed Research Centre for Pharmacoeconomics, Warsaw, Poland PID22 AN APPRAISAL OF HEALTH-RELATED QUALITY OF LIFE INSTRUMENTS FOR USE IN PATIENTS DIAGNOSED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE Joshi AV, Nau DP, Kalsekar ID, West Virginia University, Morgantown, WV, USA PID23 PATTERNS OF ANTIBIOTIC USE AND COSTS ASSOCIATED WITH EPISODES OF TREATMENT FOR COMMON OUTPATIENT RESPIRATORY-TRACT INFECTIONS: AN ANALYSIS OF MANAGED-CARE DATA Edelman-Lewis B1, Menzin J2, Boulanger L2, Lueng M2, Friedman M2, Hurley JS3, Harnett J4, Wilson J4, 1Focus Managed Research, Inc, Worcester, MA, USA; 2Boston Health Economics, Inc, Waltham, MA, USA; 3Lovelace Respiratory Research Institute, Albuquerque, NM, USA; 4Pfizer Inc, New York, NY, USA PID24 COST COMPARISON OF GATIFLOXACIN VERSUS LEVOFLOXACIN IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN AN OUTPATIENT POPULATION Bell TJ1, Loomis BR1, Mauskopf JA1, L'Italien GJ2, Gallagher KM2, 1RTI, Research Triangle Park, NC, USA; 2Bristol-Myers Squibb, Wallingford, CT, USA PID25 ECONOMIC EVALUATION OF MACROLIDES AND FLUOROQUINOLONES FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS Lachaine J1, Laurier C1, Manzi P2, 1University of Montreal, Montreal, QC, Canada; 2Abbott Laboratories Ltd, St-Laurent, QC, Canada PID26 PHARMACOECONOMIC EVALUATION OF CEFUROXIME IN ABDOMINAL HYSTERECTOMY Karpov O, Zaytsev A, Institute of Pharmacology, St-Petersburg Pavlov State Medical University, St-Petersburg, Russia PID27 DOES A DAY STILL MAKE A DIFFERENCE? A DECISION ANALYSIS OF ADULT STREPTOCOCCAL PHARYNGITIS Rousculp MD, University of Alabama at Birmingham, Birmingham, AL, USA PID28 COMPARING DIFFERENCES IN CLINICAL EFFECTIVENESS, NEPHROTOXICITY, AND COST-EFFECTIVENESS OF AMINOGLYCOSIDE THERAPY BETWEEN ALTERNATIVE DOSING PROTOCOLS Reynolds R1, Gupchup G2, Borrego M2, Raisch D2, Netravali S2, 1Lovelace Health Systems, Albuquerque, NM, USA; 2University of New Mexico, Albuquerque, NM, USA MENTAL HEALTH (PMH) PMH1 SHOULD THE 51 ITEMS OF THE SCHIZOPHRENIA OUTCOMES ASSESSMENT PROJECT (SOAP-51) BE WEIGHTED? Barr J1, Schumacher G1, Mason E1, Ohman S1, Goren J1, Hanson A2, 1Northeastern University, Boston, MA, USA; 2Massachusetts Department of Medical Assistance, Boston, MA, USA PMH2 TREATMENT COURSE AND CHARGES FOR DEPRESSED PATIENTS TREATED WITH SERTRALINE, VENLAFAXINE, AND VENLAFAXINE XR IN THE MANAGED CARE SETTING Hirschfeld R1, Eaddy M2, Grudzinski A3, 1University of Texas Medical Branch, Galveston, TX, USA; 2University of South Carolina, Columbia, SC, USA; 3Pfizer Inc, New York, NY, USA PMH3 IS DEPRESSION THE MAJOR CAUSE OF IMPAIRED QUALITY OF LIFE IN SCHIZOPHRENIC PATIENTS? Toumi M1, Pettersson Å1, Llorca PM2, Lançon C3, Aballéa S1, 1Lundbeck SA, Paris, France; 2CHU Sainte-Marie, Clermont-Ferrand, France; 3CHU Sainte Marguerite, Marseilles, France PMH4 ASSESSMENT OF PATIENTS' ATTITUDES TOWARD ANTIPSYCHOTIC TREATMENT IN A 40-WEEK RANDOMIZED, CONTROLLED TRIAL Dugar A, Stuelpner JE, Mackell JA, Miceli RJ, Pfizer Pharmaceuticals Group, Pfizer, Inc, New York, NY, USA PMH5 FROM FIRST TO SECOND: IMPACT OF PARTICIPANT CHARACTERISTICS ON THE TIME TO FIRST SWITCH IN A SCHIZOPHRENIA POPULATION Russo P1, Vasey J2, 1The MEDSTAT Group, Inc, Washington, DC, USA; 2The Pennsylvania State University, State College, PA, USA PMH6 CHANGE IN INSTRUMENTAL ACTIVITIES OF DAILY LIVING ASSOCIATED WITH ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS Edell WS1, Mayo KW2, Bailey KL2, Sandoval RI2, Adams BE1, Jensik SE1, 1Mental Health Outcomes, Lewisville, TX, USA; 2Pharmacia Corporation, Peapack, NJ, USA PMH7 CHANGE IN MALADAPTIVE BEHAVIORS ASSOCIATED WITH ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS Jensik SE1, Mayo KW2, Bailey KL2, Sandoval RI2, Edell WS1, Adams BE1, 1Mental Health Outcomes, Lewisville, TX, USA; 2Pharmacia Corporation, Peapack, NJ, USA PMH8 IMPACT OF CURRENT ANTIDEPRESSANTS ON COGNITION IN OLDER PATIENTS WITH DEPRESSION Adams BE1, Mayo KW2, Sandoval RI2, Bailey KL2, Jensik SE1, Edell WS1, 1Mental Health Outcomes, Lewisville, TX, USA; 2Pharmacia Corporation, Peapack, NJ, USA PMH9 HEALTHCARE UTILIZATION AND COSTS IN SCHIZOPHRENIC PATIENTS TAKING RISPERIDONE VERSUS OLANZAPINE IN A VETERANS ADMINISTRATION POPULATION Shermock KM1, Fuller MA2, Secic M1, Laich JS2, Durkin MB3, 1The Cleveland Clinic Foundation, Cleveland, OH, USA; 2Louis Stokes Department of Veterans Affairs Medical Center, Brecksville, OH, USA; 3Janssen Pharmaceutica, Titusville, NJ, USA PMH10 HEALTH OUTCOMES OF CHILDHOOD ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): HEALTHCARE USE AND WORK STATUS OF CAREGIVERS Noe L1, Hankin CS2, 1Ovation Research Group, Highland Park, IL, USA; 2ALZA Corporation, Mountain View, CA, USA PMH11 SCHIZOPHRENIA CARE AND ASSESSMENT PROGRAM (SCAP): THE IMPACT OF CLINICAL SYNDROME, ANTIPSYCHOTIC MEDICATION TREATMENT AND ADHERENCE ON OUTPATIENT PSYCHIATRIC UTILIZATION Russo P, Smith M, The MEDSTAT Group, Inc, Washington, DC, USA PMH12 PREVALENCE OF COMORBID ANXIETY AND DEPRESSION AMONG PATIENTS PRESCRIBED SSRI MONOTHERAPY Grotzinger KM, Chang LL, GlaxoSmithKline PLC, Collegeville, PA, USA PMH13 PRE-TREATMENT PATIENT DIFFERENCES: CHOICE OF DRUG THERAPY WITHIN SCHIZOPHRENIA Gibson PJ, Loosbrock DL, Eli Lilly and Company, Indianapolis, IN, USA PMH14 DEFICIT SYNDROME AND DRUG USE PATTERNS IN COMMUNITY-BASED SCHIZOPHRENIA CARE Russo P1, Kirkpatrick B2, 1The MEDSTAT Group, Inc, Washington, DC, USA; 2University of Maryland Psychiatric Research Center, Baltimore, MD, USA PMH15 A RETROSPECTIVE ECONOMIC EVALUATION OF OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA Zhao Z, Eli Lilly and Company, Indianapolis, IN, USA PMH16 USE OF RASCH MODELS FOR VALIDATION OF INSTRUMENTS USED IN MENTAL HEALTH EVALUATION Lançon C1, Toumi M2, Pettersson Å2, Aballéa S2, Fournier A2, 1CHU Sainte Marguerite, Marseilles, France; 2Lundbeck SA, Paris, France PMH17 TYPICAL AND ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA: ASSESSMENT OF CLINICAL AND ECONIOMIC OUTCOMES USING A MARKOV MODEL Neeser K1, Schramm W1, Brandt A1, Höffler J2, Jürgens T3, Mast O3, 1Institute for Medical Informatics and Biostatistics (IMIB), Riehen, Switzerland; 2Westfälische Klinik für Psychiatrie, Gütersloh, Germany; 3Bayer Vital GmbH, Leverkusen, Germany PMH18 HEALTHCARE UTILIZATION IN PATIENTS WITH TREATMENT RESISTANT DEPRESSION Crown WH1, Ling DCY1, Finkelstein SN2, Berndt ER2, White AS1, 1The MEDSTAT Group, Cambridge, MA, USA; 2Massachusetts Institute of Technology, Cambridge, MA, USA PMH19 RISK OF HOSPITALIZATION FOR PATIENTS WITH BIPOLAR DISORDER Ling DCY1, Bresnahan BW2, White AS1, Neslusan CA2, Crown WH1, 1The MEDSTAT Group, Cambridge, MA, USA; 2R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ, USA PMH20 DOSING OF BENZODIAZEPINE HYPNOTICS IN ELDERLY PATIENTS Young JK, Schultz D, Foster D, Heller S, Solucient, Ann Arbor, MI, USA PMH21 QUALITY OF LIFE OF NON-INSTITUTIONAL CAREGIVERS OF SCHIZOPHRENIC PATIENTS: CONTRIBUTION OF QUALITATIVE INTERVIEWS TO QUESTIONNAIRE GENERATION Auquier P1, Simeoni MC1, Azorin JM2, Lançon C2, Toumi M3, 1Public Health Department, Marseilles, France; 2CHU Sainte Marguerite, Marseilles, France; 3Lundbeck SA, Paris, France PMH22 PATTERNS OF ANTIDEPRESSANT USE AND HEALTH CARE COSTS IN DEPRESSED PATIENTS WHO RECEIVED SSRI THERAPY Wade SW1, Berzon R2, Patton MP1, Koch P3, Batra D1, 1Protocare Sciences, Santa Monica, CA, USA; 2Boehringer Ingelheim, Ridgefield, CT, USA; 3Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany PMH23 DEINSTITUTIONALIZATION OF SCHIZOPHRENIC PATIENTS: COST-CONSEQUENCES AND POLICY IMPLICATION OF INTENSIVE CASE MANAGEMENT VERSUS STANDRAD CASE MANAGEMENT Llorca PM1, Toumi M2, Hansen K2, Barré S2, François C2, 1CH Sainte-Marie, Clermont-Ferrand, France; 2Lundbeck SA, Paris, France PMH24 THE COST OF ACUTE HOSPITALIZATION FOR ANOREXIA NERVOSA AND BULIMIA O'Brien JA, Patrick AR, Caro Research Institute, Concord, MA, USA PMH25 A MODEL COMPARING OLANZAPINE AND ZIPRASIDONE IN PATIENTS WITH SCHIZOPHRENIA Alexeyeva I1, Mauskopf J1, Earnshaw S1, Gibson PJ2, Ascher-Svanum H2, Ramsey JL2, 1RTI-Health Solutions, Research Triangle Park, NC, USA; 2Eli Lilly and Company, Indianapolis, IN, USA PMH26 OUTPATIENT ANTIPSYCHOTIC USE: COMPARING ATYPICAL AND CONVENTIONAL ANTIPSYCHOTIC ADHERENCE USING A NATIONAL RETAIL PHARMACY DATA BASE Vanelli MR, Adheris, Inc, Woburn, MA, USA PMH27 COST-UTILITY ANALYSIS OF QUETIAPINE COMPARED TO RISPERIDONE IN THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA OR OTHER PSYCHOTIC DISORDERS Simons WR1, Meddis D2, 1Global Health Economics & Outcomes Research, Short Hills, NJ, USA; 2AstraZeneca, Macclesfield Cheshire, UK PMH28 DEPRESSION AND HOMELESSNESS, FRENCH INITIATIVE Emmanuelli X1, Hassin J1, Smadja C2, Taieb C2, 1Samu Social de Paris, Paris, France; 2PharmacoEconomics Programs, Pierre Fabre SA, Boulogne Billancourt, France PMH29 COST ANALYSIS OF OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF UNCONTROLLED SCHIZOPHRENIA Zhao Z, Eli Lilly and Company, Indianapolis, IN, USA PMH30 DIFFERENCES IN HEALTHCARE EXPENDITURES AMONG PATIENTS TREATED FOR DEPRESSION WITH OR WITHOUT ANXIETY Crown W1, Wan GJ2, Berndt ER3, Finkelstein SN3, Ling D1, 1The MEDSTAT Group, Cambridge, MA, USA; 2Wyeth-Ayerst Pharmaceuticals, St. Davids, PA, USA; 3Massachusetts Institute of Technology, Cambridge, MA, USA PMH31 PHARMACOECONOMIC EVALUATION OF THE TREATMENT WITH OLANZAPINE IN "REVOLVING DOOR" SCHIZOPHRENIC PATIENTS Gurovich I, Lyubov E, Shmukler A, The Moscow Research Institute of Psychiatry of the Russian Federation, Moscow, Russia PMH32 BARRIERS TO THE USE OF MEDICATIONS TO TREAT ALCOHOLISM Mark TL1, Kranzler HR2, Poole VH1, Hagen CA3, McLeod C3, Crosse SE3, 1The MEDSTAT Group, Washington, DC, USA; 2University of Connecticut School of Medicine, Farmington, CT, USA; 3Westat, Rockville, MD, USA PMH33 OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA: A COMPARISON OF COSTS AMONG TEXAS MEDICAID PATIENTS Rascati KL1, Johnsrud M1, Crismon ML1, Barber BL2, Lage MJ2, 1The Center for Pharmacoeconomic Studies - The University of Texas, Austin, TX, USA; 2Eli Lilly and Co, Indianapolis, IN, USA PMH34 SWITCHING AND AUGMENTATION OF ANTIDEPRESSANTS IN OLDER DEPRESSED PATIENTS Adams BE1, Jensik SE1, Mayo KW2, Bailey KL2, Sandoval RI2, Edell WS1, 1Mental Health Outcomes, Lewisville, TX, USA; 2Pharmacia Corporation, Peapack, NJ, USA PMH35 PATTERNS OF ANTIDEPRESSANT AND ANTIPSYCHOTIC MEDICATION USE IN MEDICAID, 1995-1999 Gregorian R, Gemmen E, The Lewin Group, Falls Church, VA, USA PMH36 DOSING OF BENZODIAZEPINE HYPNOTICS IN ELDERLY PATIENTS Young JK, Schultz D, Foster D, Heller S, Solucient, Ann Arbor, MI, USA PAIN & NEUROLOGIC DISORDERS (PPN) PPN1 AN INTERNET STUDY OF WTP FOR MIGRAINE PHARMACOTHERAPIES Lenert LA, Minh C, Jackson C, University of California, San Diego, San Diego, CA, USA PPN2 USE OF GALANTAMINE IN THE NETHERLANDS FOR THE TREATMENT OF MILD TO MODERATE ALZHEIMER'S DISEASE Caro J1, Salas M1, Getsios D1, Mehnert A2, for the AHEAD Study Group, 1Caro Research Institute, Concord, MA, USA; 2Janssen Research Foundation, Beerse, Belgium PPN3 THE IMPACT OF DEMENTIA ON CAREGIVER QUALITY OF LIFE Gold KF1, Botteman MF1, Kemp R2, Kittner B2, Pashos CL1, 1Abt Associates Clinical Trials, Bethesda, MD, USA; 2Aventis, Bridgewater, NJ, USA PPN4 UTILITY ASSESSMENTS OF OPIOID TREATMENT IN THE US, CANADA AND AUSTRALIA FOR PATIENTS WITH CHRONIC NON-MALIGNANT PAIN Schmier J1, Palmer C1, Ingham M2, Mathur S1, Dodd S3, Gourlay G4, 1MEDTAP International Inc, Bethesda, MD, USA; 2Janssen-Ortho Inc, Toronto, ON, Canada; 3Janssen Pharmaceutica, Titusville, NJ, USA; 4Flinders Medical Centre, Bedford Park, Australia PPN5 THE IMPORTANCE OF THE LONG TERM: AN ILLUSTRATION FOR BETA INTERFERON 1A IN MULTIPLE SCLEROSIS McCabe CJ, Akehurst R, University of Sheffield, Sheffield, UK PPN6 VALIDATION OF THE 24 HOUR HEADACHE DISABILITY QUESTIONNAIRE (DISQ-24) IN A SAMPLE OF HEADACHE SUFFERERS Runken MC, Kwong W, Davis K, Batenhorst A, GlaxoSmithKline, Inc, Research Triangle Park, NC, USA PPN7 A MODEL FOR PREDICTING THE INCIDENCE OF MIGRAINE IN THE IDAHO MEDICAID POPULATION Shaw J1, Joish V1, Cady PS2, 1The University of Arizona, Tucson, AZ, USA; 2Idaho State University, Pocatello, ID, USA PPN8 PSYCHOMETRIC EVALUATION OF WIDELY USED PAIN MEASURES FOR PURPOSE OF COMPUTERIZED DYNAMIC PAIN ASSESSMENT Zhao JH1, Ware JE1, Kosinski M1, Bjorner JB2, Turner-Bowker D1, 1QualityMetric, Lincoln, RI, USA; 2National Institute of Occupational Health, Copenhagen, Denmark PPN9 HOW IS PAIN FELT ACROSS COUNTRIES? THE SHORT-FORM MCGILL PAIN QUESTIONNAIRE (SF-MPQ) IN 10 LANGUAGES Conway K1, Uzun V1, Alacoque J1, Abetz L2, Melzack R3, Plante M4, 1Mapi Research Institute, Lyon, France; 2Mapi Values, Macclessfield, UK; 3McGill University, Montreal, QC, Canada; 4Pfizer Inc, Ann Arbor, MI, USA PPN10 SURVIVAL AND NURSING HOME FREE SURVIVAL (NHFS) OF AD PATIENTS Wu EQ, Hay J, University of Southern California, Los Angeles, CA, USA PPN11 THE MIGRAINE IN FRANCE IN 2000: EPIDEMIOLOGICAL DATA Henry P1, Auray JP2, Duru G2, Chazot G3, Dartigues JF4, Lanteri-Minet M5, Lucas C6, Pradalier A7, El Hasnaoui A8, Gaudin AF8, 1Hopital Pellegrin, Bordeaux, France; 2Université Claude Bernard, Lyon, France; 3Hopital Cardio Vasculaire et Neurologique, Bron, France; 4Université Bordeaux II, Bordeaux, France; 5CHU de Nice, Nice, France; 6Hospital Roger Salengro, Lille, France; 7Hopital Louis Mourier, Colombes, France; 8Laboratoire Glaxo Wellcome, Marly le Roi, France PPN12 DIFFERENCES IN HEALTH-RELATED QUALITY OF LIFE BETWEEN MIGRAINEURS WITH AND WITHOUT PROPHYLACTIC MEDICATION USE Girts TK, Lofland JH, O'Connor JP, Thomas Jefferson University, Philadelphia, PA, USA PPN13 DELAYS IN NURSING HOME PLACEMENT FOR PATIENTS WITH ALZHEIMER'S DISEASE ASSOCIATED WITH TREATMENT WITH DONEPEZIL MAY HAVE HEALTHCARE COST-SAVING IMPLICATIONS Provenzano G1, Duttagupta S2, McRae T2, Mastey V2, Ellis B1, Ieni J3, 1Battelle Centers for Public Health Research and Evaluation, Arlington, VA, USA; 2Pfizer Pharmaceuticals Group, Pfizer Inc, New York, NY, USA; 3Eisai Inc, Teaneck, NJ, USA PPN14 A PROGNOSTIC MODEL TO PREDICT QUALITY OF LIFE CHANCES AFTER SUBARACHNOID HEMORRHAGE Toth K1, Szende A2, Contreraz M1, Machovich A1, Futo J1, Nyari I1, 1National Institute of Neurosurgery, Budapest, Hungary; 2AstraZeneca, Torokbalint, Hungary PPN15 MULTIPLE PAIN RELIEF ASSESSMENT IN WOMEN UNDERGOING NATURAL VERSUS EPIDURAL DELIVERY WITH ROPIVACAIN OR BUPIVACAIN vSzende A1, Kincses ZS2, Zimanyi M3, Kadar Z4, Zorenyi G1, 1AstraZeneca, Torokbalint, Hungary; 2Semmelweis University, Budapest, Hungary; 3Albert Szentgyorgyi Medical University, Szeged, Hungary, 4Diosgyor City Hospital, Diosgyor, Hungary PPN16 ECONOMIC BURDEN AND LOSS IN QUALITY OF LIFE DUE TO LOW BACK PAIN Szende A1, Lovas K2, Szebenyi B3, Bàlint G3, Héjj G3, 1AstraZeneca, Torokbalint, Hungary; 2Semmelweis University, Budapest, Hungary; 3National Institute of Rheumatology and Physiotherapy, Budapest, Hungary PPN17 ADDRESSING PARADOXES IN ECONOMIC EVALUATIONS (EES). AN EXAMPLE USING MOTOR NEURON DISEASE (MND) Bose UK1 Burrell A1, Ward J2, 1Aventis Pharma, West Malling, UK; 2Evidence Research Unit, Macclesfield, UK PPN18 COST SAVINGS IN MIGRAINE ASSOCIATED WITH LESS CHEST PAIN ON NEW TRIPTAN THERAPY Wang JT, Barr CE, Torigoe Y, Wang EI, Rowland CR, Goldfarb SD, Pharmacia, Peapack, NJ, USA PPN19 COMPARISON OF HUI2 AND HUI3 SCORES FOR PATIENTS WITH ALZHEIMER'S DISEASE Satoko N, Yukari Y, Ikeda S, Naoki I, Keio University School of Medicine, Tokyo, Japan PPN20 ESTIMATED RESOURCE USE AND COST OF MITOXANTRONE VS PLACEBO IN PATIENTS WITH PROGRESSIVE-RELAPSING AND SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS: RESULTS FROM THE MIMS TRIAL Durgin TL, Wanke LA, Goodkin D, Ghalie R, Immunex Corporation, Seattle, WA, USA PPN21 MIGRAINE IN FRANCE IN 2000 : THERAPEUTICAL DATA Lucas C1, Lanteri-Minet M2, Auray JP3, Duru G3, Chazot G4, Dartigues JF5, Henry P6, Pradalier A7, El Hasnaoui A8, Gaudin AF8, 1Hospital Roger Salengro, Lille, France; 2CHU de Nice, Nice, France; 3Université Claude Bernard, Lyon, France; 4Hopital Cardio Vasculaire et Neurologique, Bron, France; 5Université Bordeaux II, Bordeaux, France; 6Hopital Pellegrin, Bordeaux, France; 7Hopital Louis Mourier, Colombes, France; 8Laboratoire Glaxo Wellcome, Marly le Roi, France PPN22 COMPARISON OF COSTS AND COST-EFFECTIVENESS OF OXCARBAZEPINE AND SODIUM VALPROATE FOR NEW/RECENT ONSET PARTIAL SEIZURES Bazalo G1, Sachdeo R2, Graham S3, Chang S3, Cohen A3, 1Bazalo Consulting, Scottsdale, AZ, USA; 2Robert Wood Johnson Medical School, New Brunswick, NJ, USA; 3Novartis Pharmaceuticals, East Hanover, NJ, USA URINARY & KIDNEY DISORDERS (PUR) PUR1 HEALTH STATUS OF ELDERLY DIALYSIS PATIENTS Boening AJ1, Chapman MM1, Brown RH2, Zager PG2, Meyer KB1, 1New England Medical Center, Boston, MA, USA; 2Dialysis Clinics, Inc, Albuquerque, NM, USA PUR2 EVIDENCE OF DISEASE PROGRESSION IN ADULT PATIENTS WITH AN OVERACTIVE BLADDER(OAB) Zhou Z1, Barr CE1, Torigoe Y1, Williamson TE1, Shah J2, 1Pharmacia, Peapack, NJ, USA; 2Institute of Urology, London, London, UK PUR3 PERSISTENCE OF THERAPY WITH DRUGS FOR OVERACTIVE BLADDER Zhou Z, Barr CE, Torigoe Y, Williamson TE, Pharmacia, Peapack, NJ, USA PUR4 ANALYSIS OF COMORBIDITY IN OVERACTIVE BLADDER AND URINARY INCONTINENCE IN A MANAGED CARE ORGANIZATION Juzba M, White TJ, Chang EY, Prescription Solutions, Costa Mesa, CA, USA PUR5 THE IMPACT OF PHARMACOTHERAPY ON OVERACTIVE BLADDER SYMPTOM IMPROVEMENT AND RESOURCE UTILIZATION Pashos CL1, Grossman M1, Bull S2, 1Abt Associates Clinical Trials, Cambridge, MA, USA; 2Alza Corporation, Mountain View, CA, USA PUR6 THE RELIABILITY AND VALIDITY OF A NEW OAB-SPECIFIC HRQL QUESTIONNAIRE (OAB-Q) Coyne K1, Abrams P2, Revicki D1, Herzog R3, Hunt T4, 1MEDTAP International Inc, Bethesda, MD, USA; 2Bristol Urological Institute, Bristol, UK; 3University of Michigan, Ann Arbor, MI, USA; 4Pharmacia, Peapack, NJ, USA PUR7 CLINICAL CORRELATES WITH HEALTH-RELATED QUALITY OF LIFE SCORES AND SUBSCALES AMONG CONSULTING AND NON-CONSULTING INDIVIDUALS WITH STRESS URINARY INCONTINENCE Rao S, Bowman L, Buesching D, Eli Lilly and Company, Indianapolis, IN, USA PUR8 THE INFLUENCE OF RACE ON SF-36 SCORES OF DIALYSIS PATIENTS Boening AJ1, Chapman MM1, Brown RH2, Zager PG2, Meyer KB1, 1New England Medical Center, Boston, MA, USA; 2Dialysis Clinics Inc, Albuquerque, NM, USA WOMEN & MEN'S HEALTH (PWM) PWM1 PREMATURE BIRTH AND RESOURCE UTILIZATION IN A LARGE EMPLOYMENT BASED INDEPENDENT PRACTICE ASSOCIATION (IPA) Harley CR1, Leader S2, 1Ingenix Pharmaceutical Services, Eden Prairie, MN, USA; 2MedImmune Inc, Gaithersburg, MD, USA PWM2 A COST-MINIMIZATION ANALYSIS COMPARING MIRENA® WITH ORAL CONTRACEPTIVES Menard G, Pineau M, Laplante S, Berlex Canada Inc, Lachine, Canada PWM3 ERECTILE DYSFUNCTION: A PROSPECTIVE STUDY OF PATIENTS SEEKING THERAPY Jackson-Kline SE1, Shepherd MD2, Divers EC3, Lawson KA2, Rascati KL2, Rosen RC4, 1Health Outcomes Consultant, Devon, PA, USA; 2The University of Texas, Austin, TX, USA; 3AstraZeneca, Wayne, PA, USA; 4The University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA PWM4 PHARMACIST-INITIATED EMERGENCY CONTRACEPTION IN BRITISH COLUMBIA Fielding D, Soon J, Levine M, Ensom M, The University of British Columbia, Vancouver, BC, Canada PWM5 HEALTHCARE USE ATTRIBUTABLE TO PROSTATE NON-SELECTIVE ALPHA-1 ANTAGONIST INITIATION FOR BENIGN PROSTATIC HYPERPLASIA (BPH) Chrischilles EA1, Rubenstein LM1, Gilden D2, Shah H3, 1University of Iowa, Iowa City, IA, USA; 2Jen Associates, Inc, Cambridge, MA, USA; 3Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA PWM6 COST EFFECTIVENESS OF INTRAVAGINAL PROSTAGLANDIN E2 GEL AND INTRAVAGINAL MISOPROSTOL FOR PREINDUCTION CERVICAL RIPENING Gagne AL, Daneshfar S, Northeastern University, Boston, MA, USA PWM7 THE EFFECT AND ECONOMIC IMPACT OF STANDARDIZED ORDERS ON THE PREVENTION AND TREATMENT OF PONV IN HOSPITALIZED GYNECOLOGICAL SURGERY PATIENTS Marra C, St. Pierre E, Frighetto L, Vancouver General Hospital, Vancouver, BC, Canada NO SPECIFIC OR MULTIPLE DISEASES - HEALTH POLICY (PHP) PHP1 THE ECONOMICS OF PARALLEL TRADE IN PHARMACEUTICALS: EXPERIENCES FROM SWEDEN Persson UB, Anell A, IHE, The Swedish Institute for Health Economics, Lund, Sweden PHP2 ATTITUDE OF PHYSICIANS TOWARD FORMULARIES AND SERVICES PROVIDED BY PHARMACIST Sansgiry SS1, Hayes DJ1, Rice GK2, Nadrash AT1, Erickson KE1, Bui MU1, 1University of Houston, Houston, TX, USA; 2Kelsey-Seybold Clinic, Houston, TX, USA PHP3 PHARMACOECONOMIC FELLOWSHIPS: STRUCTURE, PROCESS, AND OUTCOMES Maio V, Lofland JH, Girts TK, Thomas Jefferson University, Philadelphia, PA, USA PHP4 DEVELOPING A COMPREHENSIVE PERFORMANCE MEASUREMENT DATA SET FOR PHARMACEUTICAL BENEFIT MANAGEMENT PROGRAMS Long SR1, Hatzmann MH1, Chawla AJ2, 1The MEDSTAT Group, Washington, DC, USA; 2Genentech, South San Francisco, CA, USA PHP5 POLISH GUIDELINES FOR CONDUCTING PHARMACOECONOMIC EVALUATIONS IN COMPARISON TO INTERNATIONAL HEALTH ECONOMIC GUIDELINES Orlewska E1, Mierzejewski P2, 1Medical University of Warsaw, Warsaw, Poland; 2Ministry of Health, Warsaw, Poland PHP6 ACTIVITIES, FUNCTIONS AND STRUCTURE OF PHARMACY AND THERAPEUTICS COMMITTEES IN ISRAELI HOSPITALS Rotem R1, Reuveni H2, Goldberg A2, 1Sokoka Meidcal Centre, Beer-Sheba, Israel; 2Ben-Gurion University, Beer-Sheba, Israel PHP7 APPLICATION OF HEALTH ECONOMICS IN THE CANADIAN PHARMACEUTICAL INDUSTRY Hirji Z1, Rindress DE2, Welner SA2, 1University of British Columbia, Vancouver, BC, Canada; 2BioMedCom Consultants Inc, Montreal, QC, Canada PHP8 PRACTICE USE OF PHARMACOECONOMICS DATA IN HOSPITAL FORMULARY DECISIONS Odedina FT1, Sullivan JL2, Nash R1, Clemmons CD1, 1Florida A&M University, Tallahassee, FL, USA; 2Pharmacia Corporation, Tampa, FL, USA PHP9 COMPARISON OF TECHNOLOGY ASSESSMENT IN LARGE MEDICAL GROUPS AND HEALTH MAINTENANCE ORGANIZATIONS (HMOS) Wise S1, Donohue TF2, 1Genentech, Inc, South San Francisco, CA, USA; 2Boston Market Strategies, Inc, Lynnfield, MA, USA PHP10 THE POTENTIAL BENEFITS AND DRAWBACKS OF ALLOWING DIRECT-TO-CONSUMER ADVERTISING OF PHARMACEUTICALS IN EUROPE Dickson AJ, Consultant Health Economist, Northallerton, UK PHP11 USE OF THE ANDERSEN HEALTH CARE SERVICES UTILIZATION BEHAVIORAL MODEL TO UNDERSTAND THE RELATIONSHIP BETWEEN HEALTH INSURANCE COVERAGE AND HEALTH CARE SERVICES UTILIZATION AMONG THE ELDERLY Yang M, Barner JC, The University of Texas, Austin, TX, USA PHP12 ACUTE CARE ELDERLY UNITS: THEIR PREVALENCE, CHARACTERISTICS AND DETERMINANATS Jayadevappa R, Raziano DB, Samakur M, Lavizzo-Mourey R, University of Pennsylvania, Philadelphia, PA, USA PHP13 INDICES FOR EVALUATION OF DRUG COST/ UTILIZATION: EVERY SILVER LINING HAS A GRAY CLOUD Valuck RJ, University of Colorado School of Pharmacy, Denver, CO, USA PHP14 COST ANALYSIS OF PHARMACEUTICAL SERVICES IN A TEACHING INSTITUTION Bussières JF, Lebel D, Montreal University, Sainte-Justine Hospital, Montréal, QC, Canada PHP15 A SURVEY OF PUBLIC HOSPITAL PHARMACISTS IN SINGAPORE ON THEIR VIEWS ABOUT 'THE FORMULARY' AND ITS DECISION-MAKING PROCESS Roy A, Li SC, National University of Singapore, Singapore, Singapore PHP16 THE VALUE OF VARIOUS FORMS OF EVIDENCE IN DRUG FORMULARY DECISIONMAKING Morris L1, Aikin K2, 1Louis A. Morris & Associates, Dix Hills, NY, USA; 2Food and Drug Administration, Rockville, MD, USA PHP17 PATIENT OUTCOMES IN THE SEDATED ICU PATIENT Kamath T1, Hopefl A2, Chaikledkaew U1, Johnson KA1, 1University of Southern California, Los Angeles, CA, USA; 2AmeriNet, St. Louis, MO, USA PHP18 A MODEL FOR COMPARING COSTS ASSOCIATED WITH PRESCRIPTION WASTAGE WITH APPLICATION TO VA PRESCRIPTION DATA Walton SM, Johnson NE, Arondekar BV, Schumock GT, University of Illinois at Chicago, Chicago, IL, USA PHP19 USING FINANCIAL RATIOS TO COMPARE PHARMACY SPENDING IN THE DEPARTMENT OF VETERANS AFFAIRS Sampson JM, VA Medical Center, Alexandria, LA, USA PHP20 THE LAG BETWEEN EFFECTIVENESS AND COST-EFFECTIVENESS EVIDENCE OF NEW DRUGS AND DECISION MAKING IN HEALTH CARE Stoykova BA, Drummond M, Kleijnen J, University of York, York, UK PHP21 SINGLE EUROPEAN-LEVEL COST-EFFECTIVENESS ANALYSIS: OVER THE FOURTH HURDLE AND INTO THE DITCH? Hutton J1, Nuijten M2, Chambers M1, 1MEDTAP International Inc, London, UK; 2MEDTAP International, Jisp, Netherlands PHP22 PATIENT ADHERENCE TO DRUG THERAPY IN A THREE-TIER COPAYMENT STRUCTURE Hutchison S, AdvancePCS, Scottsdale, AZ, USA PHP23 DRUG REIMBURSEMENT PROGRAM FOR INDIGENT PATIENTS: AN ECONOMIC IMPACT ON THE HOSPTAL ADMINSTRATION BUDGET Nguyen AB1, Arbuckle R2, Anderson RW2, Sansgiry SS1, 1University of Houston, Houston, TX, USA; 2The University of Texas MD Anderson Cancer Center, Houston, TX, USA NO SPECIFIC OR MULTIPLE DISEASES - QUALITY OF LIFE & PREFERNCE-BASED MEASURES (PQP) PQP1 LESSONS LEARNED FROM DEVELOPING A PSYCHOMETRICALLY BASED SEDATION QUESTIONNAIRE IN PHARMACOLOGICALLY PARALYZED CRITICALLY ILL PATIENTS Kane SL, Dasta JF, Pathak DS, The Ohio State University, Columbus, OH, USA PQP2 ROLE OF HEALTH RELATED QUALITY OF LIFE OUTCOMES IN THE EUROPEAN DRUG REGULATORY PROCESS: A REVIEW OF THE EMEA DOCUMENTS Acquadro C, Staniek V, for the ERIQA Group, Mapi Research Institute, Lyon, France PQP3 DEFINING CLINICALLY MEANINGFUL CHANGE IN HEALTH-RELATED QUALITY OF LIFE Crosby RD1, Kolotkin RL2, Williams GR3, 1Neuropsychiatric Research Institute, Fargo, ND, USA; 2Duke Medical Center, Durham, NC, USA; 3Knoll Pharmaceuticals, Mount Olive, NJ, USA PQP4 CROSS-CULTURAL VARIATIONS IN SF-12 SCORES AMONG INDIVIDUALS WITH VARIOUS HEALTH CONDITIONS Bolge SC, Eschmann B, Donohue JA, Consumer Health Sciences, Princeton, NJ, USA PQP5 TRANSLATING SF-36 SCORES INTO PREFERENCES: AN EXAMINATION OF THE PERFORMANCE OF TWO PREDICTIVE EQUATIONS Meletiche DM, Roberts CS, Lofland JH, Thomas Jefferson University, Philadelphia, PA, USA PQP6 HEALTH UTILITIES INDEX MARK 3: AGREEMENT BETWEEN RATERS AND BETWEEN MODALITIES OF ADMINISTRATION Verrips G1, den Ouden A1, Bonsel G2, Gemke R3, Paneth N4, Verloove-Vanhorick S1, 1TNO Prevention and Health, Leiden, Netherlands; 2Academic Medical Center, Amsterdam, Netherlands; 3Free University Medical Center, Amsterdam, Netherlands; 4Michigan State University, East Lansing, MI, USA PQP7 IS COMPLIANCE WITH DRUG TREATMENT CORRELATED WITH HEALTH RELATED QUALITY OF LIFE? Côté I1, Farris KB2, Feeny DH3, 1Institute of Health Economics, Edmonton, AB, Canada; 2University of Iowa, Iowa City, IA, USA; 3Univeristy of Alberta, Edmonton, AB, Canada PQP8 EVALUATING BIAS INTRODUCED BY ANNUALIZING UTILIZATION AND COST MEASURES Zodet M, de Lissovoy G, MEDTAP International Inc, Bethesda, MD, USA PQP9 QUALITY OF LIFE OF PATIENTS WITH FABRY DISEASE Botteman MF1, Pastores GM2, Gold KF1, Yeh J1, Ali J1, Aliski W3, Pashos CL1, 1Abt Associates Clinical Trials, Bethesda, MD, USA; 2New York University School of Medicine, New York, NY, USA; 3Transkaryotic Therapies Inc, Cambridge, MA, USA PQP10 NEGATIVE AFFECTIVITY: A SIGNIFICANT CONTAMINANT OF PATIENT REPORTED HEALTH RELATED QUALITY OF LIFE INSTRUMENTS (SF-36) Reed PJ1, Moore DD2, 1University of Tennessee Health Science Center, Memphis, TN, USA; 2Clemson University, Clemson, SC, USA PQP11 THE HEALTH AND WORK QUESTIONNAIRE (HWQ): AN INSTRUMENT FOR ASSESSING WORKPLACE PRODUCTIVITY IN RELATION TO WORKER HEALTH Shikiar R1, Rentz AM2, Halpern MT3, Khan ZM4, 1MEDTAP International, Seattle, WA, USA; 2MEDTAP Intertnational Inc, Bethesda, MD, USA; 3Charles River Associates, Washington, DC, USA; 4GlaxoSmithKline, Research Triangle Park, NC, USA NO SPECIFIC OR MULTIPLE DISEASES - METHODOLOGICAL ADVANCES (PMA) PMA1 METHODOLOGICAL ADVANCES IN THE ASSESSMENT OF QUALITY OF LIFE IN CLINICAL TRIALS Hufford MR, Invivodata, Inc, Pittsburgh, PA, USA PMA2 DEVELOPMENT OF COST EFFECTIVE WEB-BASED OUTCOMES RESEARCH STUDIES AND DISEASE MANAGEMENT PROGRAMS Ambegaonkar AJ, Day D, Pfizer, Inc, Alexandria, VA, USA PMA3 DOES WHERE YOU LIVE AFFECT IF AND HOW YOU DISCOUNT FUTURE COSTS AND BENEFITS IN ECONOMIC EVALUATION? SHOULD IT? Faulkner LA1, Gafni A2, O'Brien BJ1, 1Centre for Evaluation of Medicines, St Joseph's Hospital, McMaster University, Hamilton, ON, Canada; 2McMaster University, Hamilton, ON, Canada PMA4 AN ECONOMIC PROOF AND APPLICATION THAT FORMULARY RESTRICTIONS WITHIN DRUG CLASSES ALWAYS RESULT IN HIGHER COSTS Simons WR, Global Health Economics & Outcomes Research, Inc, Short Hills, NJ, USA PMA5 A RISK ADJUSTEMENT METHODOLOGY FOR CLAIMS DATA Wilson P, Yuan Y, Dowse BT, IMS Health, Plymouth Meeting, PA, USA PMA6 THE REDUCTION OF SAMPLE SIZE FOR A COST-EFFECTIVENESS TRIAL USING A NEW METHOD: THE EIGHT CASES IN JAPAN Kamae I, Yanagisawa S, Nakahara N, Kobe University, Kobe, Japan PMA7 CONTROLLING FOR BIASES FROM MEASUREMENT ERRORS IN HEALTH OUTCOMES RESEARCH USING STRUCTURAL EQUATION MODELING Shi J, McCombs J, Hay J, Nichol M, Chou CP, Hsiao C, University of Southern California, Los Angeles, CA, USA PMA8 DEVELOPMENT OF A CHRONIC DISEASE INDICATOR USING A MANAGED CARE POPULATION Malone DC1, Raebel MA23, 1University of Arizona, Tucson, AZ, USA; 2Kaiser Permanente of Colorado, Denver, CO, USA; 3University of Colorado School of Pharmacy, Denver, CO, USA PMA9 BAYESIAN OR CLASSICAL DESIGN AND ANALYSIS: DOES IT MAKE A DIFFERENCE?? Bloom BS, University of Pennsylvania, Philadelphia, PA, USA PMA10 DESCRIPTION OF COST/EFFECTIVENESS RATIO DISTRIBUTIONS Kim S, Moeschberger M, Pathak D, The Ohio State University, Columbus, OH, USA PMA11 COMPARISON OF STATISTICAL TESTS FOR THE COST/EFFECTIVENESS RATIOS Kim S, Moeschberger M, Pathak D, The Ohio State University, Columbus, OH, USA PMA12 RELATIONSHIP BETWEEN NONPARAMETRIC RECEIVER OPERATING CHARACTERISTIC ANALYSIS AND A LIKELIHOOD-RATIO TEST FOR MODEL SELECTION: I. A MONTE CARLO SIMULATION USING CONTINUOUS DATA Shaw JW, Horrace W, Coons SJ, The University of Arizona, Tucson, AZ, USA PMA13 RELATIONSHIP BETWEEN NONPARAMETRIC RECEIVER OPERATING CHARACTERISTIC ANALYSIS AND A LIKELIHOOD-RATIO TEST FOR MODEL SELECTION: II. A MONTE CARLO SIMULATION USING DISCRETE DATA Shaw JW, Shahriar J, Horrace W, The University of Arizona, Tucson, AZ, USA PMA14 BAYESIAN DECISION ANALYSIS IN OUTCOME STUDIES WITH SMALL NUMBERS OF EVENTS: A SIMULATION BASED PREDICTION APPROACH Wang J, Davey P, MacDonald T, University of Dundee, Dundee, UK PMA15 CONDUCTING PHARMACOECONOMIC RESEARCH IN THE ABSENCE OF COUNTRY-SPECIFIC DATA Miller B1, Rosner AJ2, Becker DL2, 1Pharmacia Canada, Mississauga, ON, Canada; 2Innovus Research Inc, Burlington, ON, Canada PMA16 CONFIRMATION OF THE DECISION RULES AND ASSUMPTIONS FOR A MODEL OF DIABETES TREATMENT USING AN EXPERT PANEL Caro J1, Salas M1, Ward A1, Sung J2, Shah A2, 1Caro Research Institute, Concord, MA, USA; 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA PMA17 THE EUROPEAN SERVICE MAPPING SCHEDULE (ESMS): A NEW INSTRUMENT FOR MENTAL HEALTH SERVICES RESEARCH, RESULTS OF A FRENCH STUDY Azorin JM1, Goudemand M2, Toumi M3, Johnson S4, Pettersson A3, 1CHU Sainte Marguerite, Marseilles, France; 2Centre Hospitaliser USNB, Lille, France; 3Lundbeck SA, Paris, France; 4Whittington Hospital, Department of Psychiatry & Behavioural Sciences, London, UK PMA18 THE AVANDIA WORLDWIDE AWARENESS REGISTRY (AWARE®): AN INTERNET-BASED PROGRAM FOR EVALUATION OF CLINICAL, HUMANISTIC AND ECONOMIC OUTCOMES OF PATIENTS WITH TYPE 2 DIABETES Bakst A1, Meletiche DM1, Arnold R2, Harjono H2, Najib M2, Cobitz A1, 1GlaxoSmithKline, Collegeville, PA, USA; 2Pharmacon International, Inc, New York, NY, USA